bioAffinity Technologies Inc., a Delaware-based corporation, has entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC. This agreement allows for the sale of the company's common stock, valued at $0.007 per share, through an "at the market offering" program. Under this arrangement, shares may be sold directly on the Nasdaq Capital Market or other existing trading platforms at prevailing market prices. The company retains control over the sale parameters, including the number of shares, the timing, and any minimum price constraints. The agreement remains in effect until all shares are sold, but can be terminated by either party with a 10-day notice.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。